an innovative clinical stage biotechnology company that is developing novel pain relief treatments for osteoarthritis

Daria Lemann-Blumenthal

CEO

Prof. Michael Belkin

Founder & Medical Director

Glaucoma care in the blink of an eye

BELKIN Laser is developing an automatic one-second laser treatment for glaucoma. Glaucoma is the leading cause of irreversible blindness globally, affecting more than 60 million patients. 

BELKIN Laser’s innovative technique will revolutionize accessibility to glaucoma care by becoming the first-line choice for glaucoma therapy for patients throughout the world. It is a simple, painless, non-invasive procedure that is as effective as current first-line treatments, and it can be performed at any clinic. It is suitable for most glaucoma patients. 
 
In addition, BELKIN Laser’s innovative technology provides an exclusive solution for Angle Closure Glaucoma (ACG), the most common form of glaucoma among Asian populations.